Reduced cell-associated DNA and improved viral control in macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated simian/human immunodeficiency virus challenges

Ann Hessell, Mariya B. Shapiro, Rebecca Powell, Delphine Malherbe, Sean P. McBurney, Shilpi Pandey, Tracy Cheever, William F. Sutton, Christoph Kahl, Byung Park, Susan Zolla-Pazner, Nancy Haigwood

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A high level of V1V2-specific IgG antibodies (Abs) in vaccinees' sera was the only independent variable that correlated with a reduced risk of human immunodeficiency virus (HIV) acquisition in the RV144 clinical trial. In contrast, IgG avidity, antibody neutralization, and antibody-dependent cellular cytotoxicity each failed as independent correlates of infection. Extended analyses of RV144 samples demonstrated the antiviral activities of V1V2-specific vaccine-induced antibodies. V2-specific antibodies have also been associated with protection from simian immunodeficiency virus (SIV), and the V2ispecific subset of human monoclonal antibodies (MAbs), while poor neutralizers, mediates Fc-dependent antiviral functions in vitro. The objective of this study was to determine the protective efficacy of a V2i-specific human MAb, 830A, against mucosal simian/ human immunodeficiency virus (SHIV) challenge. V2i MAb binding sites overlap the integrin binding site in the V2 region and are similar to the epitopes bound by antibodies associated with reduced HIV infection rates in RV144. Because the IgG3 subclass was a correlate of reduced infection rates in RV144, we compared passive protection by both IgG1 and IgG3 subclasses of V2i MAb 830A. This experiment represents the first in vivo test of the hypothesis emanating from RV144 and SIV studies that V2i Abs can reduce the risk of infection. The results show that passive transfer with a single V2i MAb, IgG1 830A, reduced plasma and peripheral blood mononuclear cell (PBMC) virus levels and decreased viral DNA in lymphoid tissues compared to controls, but too few animals remained uninfected to achieve significance in reducing the risk of infection. Based on these findings, we conclude that V2i antibodies can impede virus seeding following mucosal challenge, resulting in improved virus control.

Original languageEnglish (US)
Article numbere02198-17
JournalJournal of Virology
Volume92
Issue number11
DOIs
StatePublished - Jun 1 2018

Fingerprint

Simian Immunodeficiency Virus
Human immunodeficiency virus
Viral DNA
Macaca
monoclonal antibodies
Monoclonal Antibodies
HIV
Immunoglobulin G
antibodies
Antibodies
DNA
Simian immunodeficiency virus
cells
Viruses
Infection
infection
viruses
Antiviral Agents
binding sites
Binding Sites

Keywords

  • Envelope protein
  • Gp120
  • HIV
  • Monoclonal antibody
  • Nonhuman primate models
  • Passive immunity
  • Passive transfer
  • V2 region

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Insect Science
  • Virology

Cite this

Reduced cell-associated DNA and improved viral control in macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated simian/human immunodeficiency virus challenges. / Hessell, Ann; Shapiro, Mariya B.; Powell, Rebecca; Malherbe, Delphine; McBurney, Sean P.; Pandey, Shilpi; Cheever, Tracy; Sutton, William F.; Kahl, Christoph; Park, Byung; Zolla-Pazner, Susan; Haigwood, Nancy.

In: Journal of Virology, Vol. 92, No. 11, e02198-17, 01.06.2018.

Research output: Contribution to journalArticle

Hessell, Ann ; Shapiro, Mariya B. ; Powell, Rebecca ; Malherbe, Delphine ; McBurney, Sean P. ; Pandey, Shilpi ; Cheever, Tracy ; Sutton, William F. ; Kahl, Christoph ; Park, Byung ; Zolla-Pazner, Susan ; Haigwood, Nancy. / Reduced cell-associated DNA and improved viral control in macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated simian/human immunodeficiency virus challenges. In: Journal of Virology. 2018 ; Vol. 92, No. 11.
@article{b2d87db7aad44b3099fa716450abaed1,
title = "Reduced cell-associated DNA and improved viral control in macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated simian/human immunodeficiency virus challenges",
abstract = "A high level of V1V2-specific IgG antibodies (Abs) in vaccinees' sera was the only independent variable that correlated with a reduced risk of human immunodeficiency virus (HIV) acquisition in the RV144 clinical trial. In contrast, IgG avidity, antibody neutralization, and antibody-dependent cellular cytotoxicity each failed as independent correlates of infection. Extended analyses of RV144 samples demonstrated the antiviral activities of V1V2-specific vaccine-induced antibodies. V2-specific antibodies have also been associated with protection from simian immunodeficiency virus (SIV), and the V2ispecific subset of human monoclonal antibodies (MAbs), while poor neutralizers, mediates Fc-dependent antiviral functions in vitro. The objective of this study was to determine the protective efficacy of a V2i-specific human MAb, 830A, against mucosal simian/ human immunodeficiency virus (SHIV) challenge. V2i MAb binding sites overlap the integrin binding site in the V2 region and are similar to the epitopes bound by antibodies associated with reduced HIV infection rates in RV144. Because the IgG3 subclass was a correlate of reduced infection rates in RV144, we compared passive protection by both IgG1 and IgG3 subclasses of V2i MAb 830A. This experiment represents the first in vivo test of the hypothesis emanating from RV144 and SIV studies that V2i Abs can reduce the risk of infection. The results show that passive transfer with a single V2i MAb, IgG1 830A, reduced plasma and peripheral blood mononuclear cell (PBMC) virus levels and decreased viral DNA in lymphoid tissues compared to controls, but too few animals remained uninfected to achieve significance in reducing the risk of infection. Based on these findings, we conclude that V2i antibodies can impede virus seeding following mucosal challenge, resulting in improved virus control.",
keywords = "Envelope protein, Gp120, HIV, Monoclonal antibody, Nonhuman primate models, Passive immunity, Passive transfer, V2 region",
author = "Ann Hessell and Shapiro, {Mariya B.} and Rebecca Powell and Delphine Malherbe and McBurney, {Sean P.} and Shilpi Pandey and Tracy Cheever and Sutton, {William F.} and Christoph Kahl and Byung Park and Susan Zolla-Pazner and Nancy Haigwood",
year = "2018",
month = "6",
day = "1",
doi = "10.1128/JVI.02198-17",
language = "English (US)",
volume = "92",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Reduced cell-associated DNA and improved viral control in macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated simian/human immunodeficiency virus challenges

AU - Hessell, Ann

AU - Shapiro, Mariya B.

AU - Powell, Rebecca

AU - Malherbe, Delphine

AU - McBurney, Sean P.

AU - Pandey, Shilpi

AU - Cheever, Tracy

AU - Sutton, William F.

AU - Kahl, Christoph

AU - Park, Byung

AU - Zolla-Pazner, Susan

AU - Haigwood, Nancy

PY - 2018/6/1

Y1 - 2018/6/1

N2 - A high level of V1V2-specific IgG antibodies (Abs) in vaccinees' sera was the only independent variable that correlated with a reduced risk of human immunodeficiency virus (HIV) acquisition in the RV144 clinical trial. In contrast, IgG avidity, antibody neutralization, and antibody-dependent cellular cytotoxicity each failed as independent correlates of infection. Extended analyses of RV144 samples demonstrated the antiviral activities of V1V2-specific vaccine-induced antibodies. V2-specific antibodies have also been associated with protection from simian immunodeficiency virus (SIV), and the V2ispecific subset of human monoclonal antibodies (MAbs), while poor neutralizers, mediates Fc-dependent antiviral functions in vitro. The objective of this study was to determine the protective efficacy of a V2i-specific human MAb, 830A, against mucosal simian/ human immunodeficiency virus (SHIV) challenge. V2i MAb binding sites overlap the integrin binding site in the V2 region and are similar to the epitopes bound by antibodies associated with reduced HIV infection rates in RV144. Because the IgG3 subclass was a correlate of reduced infection rates in RV144, we compared passive protection by both IgG1 and IgG3 subclasses of V2i MAb 830A. This experiment represents the first in vivo test of the hypothesis emanating from RV144 and SIV studies that V2i Abs can reduce the risk of infection. The results show that passive transfer with a single V2i MAb, IgG1 830A, reduced plasma and peripheral blood mononuclear cell (PBMC) virus levels and decreased viral DNA in lymphoid tissues compared to controls, but too few animals remained uninfected to achieve significance in reducing the risk of infection. Based on these findings, we conclude that V2i antibodies can impede virus seeding following mucosal challenge, resulting in improved virus control.

AB - A high level of V1V2-specific IgG antibodies (Abs) in vaccinees' sera was the only independent variable that correlated with a reduced risk of human immunodeficiency virus (HIV) acquisition in the RV144 clinical trial. In contrast, IgG avidity, antibody neutralization, and antibody-dependent cellular cytotoxicity each failed as independent correlates of infection. Extended analyses of RV144 samples demonstrated the antiviral activities of V1V2-specific vaccine-induced antibodies. V2-specific antibodies have also been associated with protection from simian immunodeficiency virus (SIV), and the V2ispecific subset of human monoclonal antibodies (MAbs), while poor neutralizers, mediates Fc-dependent antiviral functions in vitro. The objective of this study was to determine the protective efficacy of a V2i-specific human MAb, 830A, against mucosal simian/ human immunodeficiency virus (SHIV) challenge. V2i MAb binding sites overlap the integrin binding site in the V2 region and are similar to the epitopes bound by antibodies associated with reduced HIV infection rates in RV144. Because the IgG3 subclass was a correlate of reduced infection rates in RV144, we compared passive protection by both IgG1 and IgG3 subclasses of V2i MAb 830A. This experiment represents the first in vivo test of the hypothesis emanating from RV144 and SIV studies that V2i Abs can reduce the risk of infection. The results show that passive transfer with a single V2i MAb, IgG1 830A, reduced plasma and peripheral blood mononuclear cell (PBMC) virus levels and decreased viral DNA in lymphoid tissues compared to controls, but too few animals remained uninfected to achieve significance in reducing the risk of infection. Based on these findings, we conclude that V2i antibodies can impede virus seeding following mucosal challenge, resulting in improved virus control.

KW - Envelope protein

KW - Gp120

KW - HIV

KW - Monoclonal antibody

KW - Nonhuman primate models

KW - Passive immunity

KW - Passive transfer

KW - V2 region

UR - http://www.scopus.com/inward/record.url?scp=85046893445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046893445&partnerID=8YFLogxK

U2 - 10.1128/JVI.02198-17

DO - 10.1128/JVI.02198-17

M3 - Article

C2 - 29514914

AN - SCOPUS:85046893445

VL - 92

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 11

M1 - e02198-17

ER -